Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 3/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 6/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.42 |
| ▸ | CCNK | O75909 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5414003 | 0.82 | JAK2 (0.56) | JAK2LRRK2SYKAURKAKDR | |
| SCHEMBL5413853 | 0.82 | JAK2 (0.68) | JAK2LRRK2SYKPTK2AURKA | |
| SCHEMBL5414043 | 0.78 | GSK3B (0.59) | JAK2LRRK2SYKPTK2AURKA | |
| SCHEMBL5405530 | 0.77 | L3MBTL1 (0.57) | JAK2LRRK2SYKAURKAMEN1 | |
| SCHEMBL655316 | 0.77 | AURKA (0.69) | JAK2SYKPTK2AURKAFLT3 | |
| SCHEMBL5402321 | 0.76 | STK17A (0.55) | JAK2LRRK2AURKAMEN1MAPT | |
| SCHEMBL12705392 | 0.74 | AURKA (0.58) | SYKAURKACDK2MAPTRAB9A | |
| SCHEMBL12876567 | 0.74 | LRRK2 (0.39) | JAK2LRRK2SYKAURKAKIT | |
| SCHEMBL12065029 | 0.74 | ALK (0.63) | SYKFLT3CCNKCCND3CDK9 | |
| SCHEMBL5514474 | 0.74 | SYK (0.65) | JAK2LRRK2SYKAURKACCNK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1453516-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
| WO-2003032994-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | JAK2 4450/4885LRRK2 619/4885SYK 1842/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | JAK2 4231/4885LRRK2 775/4885SYK 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.